Medtronic, Inc. Panel Unanimously Recommends Approval Of Third Indication For FDA’s INFUSE Bone Graft

MEMPHIS, Tenn.--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) today announced that the FDA Dental Products Advisory Panel has unanimously voted to recommend approval, with a condition the use of INFUSE® Bone Graft for certain oral and maxillofacial bone grafting procedures. This will be the third Premarket Approval Application (PMA) voted for panel approval since 2002 for INFUSE Bone Graft. The condition surrounds the wording of the product labeling.